The stock reaction is likely to be muted as the filing contains no clinical data readouts or near-term catalysts. Monitor upcoming SID meeting in May 2026 for preclinical data presentation and track enrollment progress in the ADAPTIVE trial for potential acceleration of the timeline.
Price Chart
Executive Summary
ImageneBio reported its Q4 and full-year 2025 financial results, highlighting a strong cash position of $135.3 million post-merger and ongoing Phase 2b ADAPTIVE trial for IMG-007 in atopic dermatitis. While R&D spending decreased slightly, G&A expenses more than doubled due to merger-related and personnel costs, leading to a wider net loss. No revenue or earnings guidance was provided, and the company remains in clinical development with no near-term commercial catalysts.
Key Financial Metrics
Key Facts
- Ended 2025 with $135.3 million in cash, up from $12.1 million in 2024, due to a reverse merger and $75 million private placement.
- R&D expenses decreased to $3.3M in Q4 2025 from $3.8M in Q4 2024.
- G&A expenses rose to $5.2M in Q4 2025 from $2.4M in Q4 2024, driven by merger costs and stock-based compensation.
- Net loss widened to $6.9M in Q4 2025 from $4.8M in Q4 2024.
- Full-year 2025 net loss was $45.3M vs. $36.6M in 2024; license revenue declined to $800K from $3.5M.
- IMG-007 Phase 2b trial ongoing with topline data expected in 2027; protocol amendment submitted to expand dosing regimens.
- No safety concerns reported; no cases of pyrexia, ulcers, or malignancies observed.
Financial Impact
License revenue declined 77% YoY to $800K; full-year net loss increased 24% to $45.3M. Cash position strengthened to $135.3M, sufficient to fund operations into late-stage trials.
Risk Factors
- Clinical development risk: IMG-007 is still in Phase 2b with topline data not expected until 2027.
- Revenue concentration: License revenue dropped sharply from $3.5M to $800K, indicating reliance on non-core, one-time income sources.
- Increasing G&A costs: Rising administrative expenses post-merger could pressure cash runway if not managed.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3252746 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Aug 7, 2026 8w ago | EFFECT | $5.69 $4.85 | ▲ +14.76% | ▲ +14.37% | $4.60 (+19.16%) |
Jun 26, 2026 14w ago | 8-K | $6.07 $5.59 | ▼ −7.91% | ▼ −7.63% | $4.60 (−24.22%) |
Apr 30, 2026 22w ago | DEFA14A | $5.66 $5.47 | ▼ −3.36% | ▼ −8.62% | $4.60 (−18.73%) |
Apr 13, 2026 24w ago | 8-K | $6.05 $5.61 | ▲ +7.27% | ▲ +15.00% | $4.60 (+23.97%) |
Apr 13, 2026 24w ago | Press Release | $6.05 $5.61 | ▲ +7.27% | ▲ +15.00% | $4.60 (+23.97%) |
Apr 6, 2026 25w ago | EFFECT | $4.55 $5.72 | ▲ +25.60% | ▲ +16.62% | $4.60 (+1.10%) |
Mar 17, 2026 28w ago | Press Release | $5.83 $5.78 | ▼ −0.77% | ▼ −6.82% | $4.60 (−21.03%) |
Mar 10, 2026 29w ago | Press Release | $6.07 $4.57 | ▼ −24.71% | ▼ −24.56% | $4.60 (−24.22%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access